US 6756399
Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
expired A61KA61K31/405A61K45/06
Quick answer
US patent 6756399 (Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jun 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.
Key facts
- Applicant
- The United States of America, as represented by the Department of Health and Human Services
- Grant date
- Tue Jun 29 2004 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 55
- CPC classes
- A61K, A61K31/405, A61K45/06